GBIO vs. SAVA, VXRT, CRDL, KRRO, VIRI, ADAG, ORMP, OPTN, HLVX, and CCCC
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Cassava Sciences (SAVA), Vaxart (VXRT), Cardiol Therapeutics (CRDL), Korro Bio (KRRO), Virios Therapeutics (VIRI), Adagene (ADAG), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), HilleVax (HLVX), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.
Generation Bio vs. Its Competitors
Generation Bio (NASDAQ:GBIO) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.
Cassava Sciences has a net margin of 0.00% compared to Generation Bio's net margin of -782.86%. Cassava Sciences' return on equity of -88.05% beat Generation Bio's return on equity.
In the previous week, Generation Bio had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Generation Bio and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 1.61 beat Generation Bio's score of 1.43 indicating that Cassava Sciences is being referred to more favorably in the news media.
Cassava Sciences received 50 more outperform votes than Generation Bio when rated by MarketBeat users. However, 72.73% of users gave Generation Bio an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote.
Generation Bio presently has a consensus price target of $7.33, indicating a potential upside of 1,814.71%. Cassava Sciences has a consensus price target of $54.50, indicating a potential upside of 2,470.75%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Generation Bio.
Generation Bio has a beta of 2.66, indicating that its stock price is 166% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -1.99, indicating that its stock price is 299% less volatile than the S&P 500.
Cassava Sciences has lower revenue, but higher earnings than Generation Bio. Cassava Sciences is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 21.8% of Generation Bio shares are owned by insiders. Comparatively, 2.4% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Generation Bio beats Cassava Sciences on 11 of the 17 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GBIO) was last updated on 6/12/2025 by MarketBeat.com Staff
